Sermorelin research: the GHRH(1-29) studies on the aging GH/IGF-1 axis

The short version

Here is the sermorelin research in one breath. Sermorelin is a GHRH(1-29) peptide that lands on the GHRH receptor in the pituitary gland and tells it to release the body's own growth hormone (GH), which then drives IGF-1 from the liver ^[6]. The most-cited human study put it in older men and watched their GH and IGF-1 climb back toward young-adult levels in two weeks ^[2]. The oldest and most solid use is in growth-hormone-deficient children, where it sped up growth ^[1].

A lot of the modern body-composition and cognition data actually comes from a longer-lasting cousin, tesamorelin ^[7], which we keep clearly separated. And the headline caution is from a 2008 editorial that called anti-aging secretagogue use "not yet ready for prime time" ^[5]. Below, each finding gets its own section, with the study and the numbers.

The mechanism: how sermorelin moves the GH/IGF-1 axis

Sermorelin is the 1-29 N-terminal fragment of GHRH — the shortest fragment that keeps the hormone's full activity ^[6]. It binds the GHRH receptor (a class B G-protein-coupled receptor) on the pituitary's growth-hormone cells, which raises cAMP, activates PKA, and triggers the synthesis and pulsed release of GH ^[6]. GH then travels to the liver and drives IGF-1, the hormone that carries out much of GH's downstream effect ^[6].

The design choice that defines sermorelin: it acts upstream, on the gland, not by supplying GH directly. So the body's feedback loops stay intact. Somatostatin (the "enough" signal) and IGF-1 feedback continue to regulate the system, and the natural pulse pattern of GH is preserved ^[4][11]. Older work mapping GH autofeedback — including the roles of free fatty acids and somatostatin — shows those brakes still operate during GHRH-driven stimulation ^[11]. A 2025 review in a top endocrinology journal synthesizes this GHRH biology, the receptor signaling, and the therapeutic landscape of GHRH agonists and antagonists in full ^[6].

Does sermorelin work

On the does sermorelin work question, the answer from the cited human data is: yes, for the specific thing it was designed to do — moving the GH/IGF-1 axis. In healthy older men (mean 68), GHRH(1-29) at 0.5 mg and 1 mg twice daily for 14 days produced dose-related increases in 24-hour GH and IGF-1; at the high dose those measures matched young men's, with no fasting-glucose change ^[2]. A pharmacokinetic study in 30 healthy men confirmed dose-dependent GH release from intravenous GHRH(1-29), with GH staying elevated about three hours despite rapid clearance of the peptide ^[3]. Whether that lab effect translates into the long-term anti-aging outcomes people hope for is the open question the literature has not closed ^[5].

The aging GH/IGF-1 axis: the lead evidence

The aging story is sermorelin's center of gravity. Natural GHRH-driven GH secretion falls with age, and the older-men trial showed a GHRH peptide could reverse the age-related drop in GH and IGF-1 over two weeks ^[2]. An editorial argued that, because sermorelin preserves pulsatile GH release and pituitary feedback, it may be a more physiologic approach to adult-onset low GH than injecting recombinant growth hormone ^[4].

The cognition thread runs alongside it. In a randomized, double-blind, placebo-controlled trial of 152 older adults (66 with mild cognitive impairment), 20 weeks of a GHRH analog (tesamorelin, 1 mg/day before bed) had a favorable effect on cognition (P=0.03), raised IGF-1 by 117% within the physiologic range, and reduced percent body fat by 7.4% ^[7]. A narrative review frames the age-related GH/IGF-1 decline and IGF-1's neuroprotective role as a candidate target in Alzheimer's disease, while noting GHRH-stimulated GH responses in patients are mixed ^[9]. And an observational study after cranial radiotherapy found that lower GHRH-stimulated GH secretion tracked with worse attention and memory ^[10] — consistent with the idea that the GH/IGF-1 axis matters for brain function, though that is association, not proof of a sermorelin treatment effect.

Pediatric growth: the most established result

The strongest, oldest sermorelin evidence is in children. In a multicenter trial of prepubertal growth-hormone-deficient children, once-daily subcutaneous GHRH(1-29) accelerated linear growth — first-year height velocity rose from about 4.1 cm/year to roughly 7-8 cm/year — without generating excessive IGF-1 ^[1]. This is the use sermorelin was actually approved for, and it's the cleanest demonstration that the peptide produces a real, measurable outcome and not just a lab-number bump ^[1].

Recent reviews (2024-2026)

The newest literature keeps the focus on the brain and the axis. A 2026 study in Alzheimer's-disease models reported that GHRH reduced amyloid-beta deposition, tau phosphorylation, neuroinflammation, and synaptic loss while improving cognitive performance — a preclinical, hypothesis-generating result, not a human treatment claim ^[12]. A 2024 brain-morphometry study in people with lifelong untreated GH deficiency found preserved brain structure and an unaltered estimated brain-aging trajectory ^[13]. And a 2025 review placed GHRH within the central and peripheral regulation of the whole GH/IGF-1 axis ^[14]. Together they keep the aging-and-cognition angle active without overstating what's been shown in humans.